Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

25.55 +0.34 (+1.35%)

Delayed Quote Updated: 10:39 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX

February 14, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX

February 08, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm

February 07, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

What 8 Analyst Ratings Have To Say About Pacira BioSciences ↗

January 30, 2025

Via Benzinga

6 Analysts Assess Pacira BioSciences: What You Need To Know ↗

January 13, 2025

Via Benzinga

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2025

From Pacira BioSciences

Via GlobeNewswire

February 04, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

February 04, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Despite its impressive fundamentals, NASDAQ:PCRX remains undervalued. ↗

February 03, 2025

Consider PACIRA BIOSCIENCES INC as a top value stock. NASDAQ:PCRX shines in terms of profitability, solvency, and liquidity, all while remaining very reasonably priced.

Via Chartmill

PCRX Stockholders Should Contact Shareholder Rights Firm Robbins for Information About the Class Action Against Pacira BioSciences, Inc.

January 31, 2025

From Robbins LLP

Via GlobeNewswire

January 31, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX

January 30, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Pacira Announces Updates to Board of Directors

January 30, 2025

From Pacira BioSciences

Via GlobeNewswire

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

January 29, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

January 26, 2025

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

January 24, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

January 22, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments

January 21, 2025

From Pacira BioSciences

Via GlobeNewswire

PCRX Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Shareholders of the Class Action Lawsuit Against Pacira BioSciences, Inc.

January 17, 2025

From Robbins LLP

Via GlobeNewswire

PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

January 17, 2025

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

January 17, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

PACIRA BIOSCIENCES SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

January 15, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law Firm

January 14, 2025

From The Schall Law Firm

Via Business Wire

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

January 14, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Rosen Law Firm Urges Pacira BioSciences, Inc. (NASDAQ: PCRX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

January 13, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

January 13, 2025

PACIRA BIOSCIENCES INC (NASDAQ:PCRX), an undervalued stock with good fundamentals.

Via Chartmill

TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday ↗

January 10, 2025

Via Benzinga

Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization

January 10, 2025

Company also reports preliminary unaudited 2024 revenue of $701.0 million

From Pacira BioSciences

Via GlobeNewswire

Pacira BioSciences Secures FDA Approval For New iovera SmartTip to Manage Chronic Low Back Pain ↗

January 07, 2025

Pacira launches a new iovera° Smart Tip for chronic back pain relief, offering an alternative to radiofrequency ablation with promising study results.

Via Benzinga

Pacira BioSciences Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block

January 07, 2025

From Pacira BioSciences

Via GlobeNewswire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.